Ginkgo Bioworks Partners with Carnegie Mellon for POSEIDON Program to Develop Diagnostic Tools
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Ginkgo Bioworks announced its partnership with Carnegie-Mellon University for an award by the Advanced Research Projects Agency for Health for its POSEIDON program. With Ginkgo Bioworks serving as the Commercial Partner, the project will also be led by Rebecca Taylor, professor of mechanical engineering at Carnegie Mellon University. As part of this team, Ginkgo plans to apply its cell and enzyme engineering expertise to support development of these new diagnostic tools. In addition to Carnegie Mellon researchers, the multidisciplinary project team includes academic experts from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, as well as corporate partners at Ginkgo Bioworks, Velentium Medical, Clinical Research Strategies, and Platypus Bio.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on DNA
Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
0 Hold
2 Sell
Moderate Sell
Current: 9.430
Low
12.00
Averages
12.00
High
12.00
Current: 9.430
Low
12.00
Averages
12.00
High
12.00
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ginkgo Bioworks CEO Jason Kelly to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Schedule: Ginkgo Bioworks Co-Founder and CEO Jason Kelly is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, showcasing the company's latest advancements in bioengineering.
- Investor Relations: Detailed information and presentation slides will be posted on the company's investor relations website, aimed at enhancing communication with investors and increasing transparency to attract potential investors.
- Technological Innovation: Ginkgo Bioworks offers customizable R&D solutions, including protein engineering and cell-free systems, which help partners accelerate innovation and drive advancements in therapeutics, diagnostics, and manufacturing, highlighting the company's leadership in biotechnology.
- Biosecurity Strategy: Ginkgo Biosecurity is building next-generation infrastructure and technologies to address various biological threats, indicating the company's strategic importance and market demand in the global biosecurity sector.
Continue Reading
Ginkgo Bioworks Partners with Carnegie Mellon to Develop Cancer Detection Technology
- Strategic Partnership: Ginkgo Bioworks has partnered with Carnegie Mellon University to support the POSEIDON program, which aims to develop an orally administered pill that detects tumor-specific signals, potentially revolutionizing early cancer detection and intervention strategies in oncology.
- Technology Application: As the designated commercial partner, Ginkgo will leverage its proprietary cell and enzyme engineering expertise to accelerate the development of these diagnostic tools, which are expected to significantly enhance the accuracy and non-invasiveness of cancer screening.
- Market Reaction: Following the announcement, Ginkgo Bioworks' shares surged over 8% to $8.77, reflecting investor optimism regarding the partnership's potential, while market data indicates a momentum score of 25.95 for the stock, showcasing strong market interest.
- Investor Focus: Despite the price increase, Ginkgo's current trading price remains approximately 16.6% below key technical levels, suggesting that investors may remain cautious in seeking signs of a turnaround before committing to longer positions, which could impact future investment decisions.
Continue Reading